Investigational Drug Information for Norketotifen
What is the development status for investigational drug Norketotifen?
Norketotifen is an investigational drug.
There have been 4 clinical trials for Norketotifen.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2019.
The most common disease conditions in clinical trials are Influenza, Human, Conjunctivitis, Allergic, and Rhinitis, Allergic. The leading clinical trial sponsors are Emergo Therapeutics, Inc. and [disabled in preview].
There are forty-six US patents protecting this investigational drug and one hundred and one international patents.
Summary for Norketotifen
| US Patents | 46 |
| International Patents | 101 |
| US Patent Applications | 121 |
| WIPO Patent Applications | 39 |
| Japanese Patent Applications | 17 |
| Clinical Trial Progress | Phase 2 (2019-04-01) |
| Vendors | 27 |
Recent Clinical Trials for Norketotifen
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness | Emergo Therapeutics, Inc. | Phase 2 |
| Norketotifen for the Treatment of Uncomplicated Influenza-like Illness | Emergo Therapeutics, Inc. | Phase 2 |
| Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis | Emergo Therapeutics, Inc. | Phase 2 |
Clinical Trial Summary for Norketotifen
Top disease conditions for Norketotifen
Top clinical trial sponsors for Norketotifen
US Patents for Norketotifen
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Norketotifen | ⤷ Start Trial | Anti-allergy benzocycloheptathiophene derivatives | Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd (Fujian, CN) | ⤷ Start Trial |
| Norketotifen | ⤷ Start Trial | Compositions for the treatment of cataracts | Catacore, Inc. (West Richland, WA) | ⤷ Start Trial |
| Norketotifen | ⤷ Start Trial | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | Emergo Therapeutics Inc | ⤷ Start Trial |
| Norketotifen | ⤷ Start Trial | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | Emergo Therapeutics Inc | ⤷ Start Trial |
| Norketotifen | ⤷ Start Trial | Methods of treatment of asthma and COPD | Bridge Pharma Inc | ⤷ Start Trial |
| Norketotifen | ⤷ Start Trial | Mast cell stabilizers for treatment of fever | Emergo Therapeutics Inc | ⤷ Start Trial |
| Norketotifen | ⤷ Start Trial | Triamcinolone and moxifloxacin compositions | Somerset Therapeutics LLC | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Norketotifen
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Norketotifen | China | CN103619839 | 2031-06-28 | ⤷ Start Trial |
| Norketotifen | European Patent Office | EP2727919 | 2031-06-28 | ⤷ Start Trial |
| Norketotifen | Japan | JP2014526438 | 2031-06-28 | ⤷ Start Trial |
| Norketotifen | Japan | JP5978296 | 2031-06-28 | ⤷ Start Trial |
| Norketotifen | World Intellectual Property Organization (WIPO) | WO2013000406 | 2031-06-28 | ⤷ Start Trial |
| Norketotifen | Australia | AU2016298951 | 2035-07-27 | ⤷ Start Trial |
| Norketotifen | Canada | CA2993196 | 2035-07-27 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
